Novartis — Sandoz
Tracked across 8 events · 68 articles · First seen Oct 29, 2025 · Last active Sep 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Novartis — Sandoz Malaysia co-launched the initiative, supplying affordable medicines and strengthening its position in the Malaysian cardiovascular market, potentially increasing sales of stroke prevention drugs.
Sep 03, 2026 · 6 articles
Business
mAbxience, a majority-owned company of Fresenius (company) with partial ownership from Insud Pharma, and Novartis — Sandoz announced a licensing, development, manufacturing and commercialization agreement for a proposed emicizumab biosimilar candidate referencing Hemlibra, indicated for…
Impact: Novartis — Sandoz secures exclusive global commercialization rights outside Argentina, Uruguay, and Paraguay, strengthening its biosimilars portfolio and long-term growth outlook.
Sep 18, 2026 · 8 articles
Tech
Impact: Novartis — Sandoz validated the J.TRAIN model through a December 2025 transaction, which included a manufacturing facility and a license to Evotec's proprietary manufacturing technology, demonstrating the feasibility and scalability of the new offering.
Jun 30, 2026 · 7 articles
Business
Impact: Nimish Muzumdar previously served as Senior Vice President & Head, Generics at Novartis — Sandoz before joining Embecta.
Jun 16, 2026 · 6 articles
Business
Novartis announced on September 8, 2026 that its Phase III HARBOR study of del-desiran, an antibody oligonucleotide conjugate for myotonic dystrophy type 1 (DM1), failed to show statistically significant improvement versus placebo on the primary…
Impact: Novartis — Sandoz, spun off from Novartis in 2023, has reportedly outperformed Novartis, adding to analyst criticism of the parent company's strategic direction.
Sep 08, 2026 · 21 articles
Business
Impact: Novartis — Sandoz expanded its development and commercialization partnership with Samsung Biologics — Samsung Biologics for biosimilar candidates.
Apr 23, 2026 · 6 articles
Domestic
Impact: Novartis — Sandoz>>> ended on a firm note and gained 1%-1.5%, contributing to the positive close of the Switzerland>>> market.
May 21, 2026 · 8 articles
Business
Impact: Patrick Vink held senior executive roles at Novartis — Sandoz.
Jul 08, 2026 · 6 articles
95
mAbxience signed collaboration agreement Novartis — SandozmAbxience Sandoz...
70
mAbxience granted exclusive commercialization rights Novartis — SandozmAbxience Sandoz...
ERGEN INTELLIGENCE
Track Novartis — Sandoz live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard